MaxCyte (MXCT) Stephens Annual Investment Conference summary

Strategic focus and recent changes

• CFO transition underway, with the outgoing CFO staying on as an advisor until a replacement is found, supporting continued development of finance and accounting functions.

• Operational restructuring reduced headcount to about 89-90 employees, refocusing on scientific, engineering, commercial, and field application support teams.

• SecureDx acquisition enhances early engagement with customers, especially in safety and engineering aspects of cell and gene therapy development.

• Integration of SecureDx positions the company to address FDA's increasing focus on safety and off-target risk in gene editing.

• Strategic platform licensing (SPL) model continues to drive customer stickiness and breadth.

Product offerings and differentiation

• Core technology is non-viral electroporation for ex vivo cell engineering, supporting both autologous and allogeneic therapies.

• Platform enables scalability from early research to clinical and commercial stages, accommodating various gene editing tools.

• SecureDx provides variant-aware analysis for off-target effects, addressing FDA concerns and expanding early customer engagement.

• New ExPERT platform extension set for commercial launch early next year, targeting earlier research phases and broadening customer reach.

• Over 1,000 protocols developed for diverse cell types and gene editing tools, supporting a wide range of indications.

Market trends and demand

• Industry headwinds include rationalization of clinical programs and customer consolidation, leading to fewer licenses but more focused development.

• Despite headwinds, three to five SPLs are signed annually, with recent growth in Asia and continued global expansion.

• Shift from viral to non-viral delivery methods driven by safety concerns, with increasing interest in allogeneic therapies.

• Broadening of cell therapy applications beyond blood cancers to solid tumors, autoimmune, and rare diseases.

• FDA validation of SecureDx technology and increased demand for early safety assessments support future growth.